Affiliation:
1. 1Assistant Professor, Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT 05446
Abstract
The acetylcholinesterase inhibitor donepezil has been in clinical use for the treatment of Alzheimer's disease since 1996. The patent on the medication expired in November 2010, and at approximately the same time, a new dosage form of donepezil was FDA approved for moderate to severe Alzheimer's disease. This article discusses the benefits and risks of the new 23 mg sustained-release dosage form compared with donepezil 10 mg, based on the clinical trial data.
Publisher
College of Psychiatric and Neurologic Pharmacists (CPNP)
Subject
Pharmacology (medical),Neurology (clinical),General Pharmacology, Toxicology and Pharmaceutics,Neuropsychology and Physiological Psychology
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献